Cargando…

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine

BACKGROUND: Development of abuse-deterrent formulations (ADFs) of prescription opioids (RxO) is an important step toward reducing misuse and abuse. Morphine-ARER (MorphaBond™ ER) is an extended-release (ER) morphine sulfate tablet formulated to deter misuse/abuse via intravenous (IV) and intranasal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossiter, Louis F, Kwong, Winghan Jacqueline, Marrett, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974417/ https://www.ncbi.nlm.nih.gov/pubmed/32021338 http://dx.doi.org/10.2147/CEOR.S226607

Ejemplares similares

A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine
por: Kinzler, Eric R., et al.
Publicado: (2019)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management
por: Marrett, Elizabeth, et al.
Publicado: (2016)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology
por: Darwish, Mona, et al.
Publicado: (2015)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
por: Crudele, Nancy T., et al.
Publicado: (2017)

Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials
por: Taber, Louise, et al.
Publicado: (2017)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Can abuse deterrent formulations make a difference? Expectation and speculation
por: Budman, Simon H, et al.
Publicado: (2009)

Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
por: Rauck, Richard L.
Publicado: (2019)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain
por: Hale, Martin E, et al.
Publicado: (2015)

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2015)

Response to Crudele et al. Commentary on Gudin et al. “Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties”
por: Gudin, Jeff, et al.
Publicado: (2017)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016
por: Zah, Vladimir, et al.
Publicado: (2019)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects
por: Webster, Lynn R., et al.
Publicado: (2018)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

Understanding the Effect of Osteoarthritis on Surgical Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients With Tenosynovial Giant Cell Tumors
por: Lin, Feng, et al.
Publicado: (2023)

Safe Opioid Storage and Disposal: A Survey of Patient Beliefs and Practices
por: Gregorian, Razmic, et al.
Publicado: (2020)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

An overview of abuse-deterrent opioids and recommendations for practical patient care
por: Adler, Jeremy A, et al.
Publicado: (2018)

Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program
por: L. Keast, Shellie, et al.
Publicado: (2016)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology
por: Dasgupta, Nabarun, et al.
Publicado: (2021)

How did you know you got the right pill? Prescription opioid identification and measurement error in the abuse deterrent formulation era
por: Green, Traci C, et al.
Publicado: (2015)

Epidural Injection of Extended-Release Morphine During Colorectal Surgery
por: Kang, Sung-Bum
Publicado: (2014)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j1c485amcbu5lmu0n4j50pkloh